Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.
Surg Today. 2019 Jul;49(7):547-555. doi: 10.1007/s00595-019-1766-8. Epub 2019 Feb 18.
Surgical intervention after induction chemoradiation is designed as curative treatment for resectable stage III/N2 non-small cell lung cancer. However, there is no definitive evidence to support this approach, possibly because successful treatment requires certain "arts", such as proper patient selection, an appropriate induction regimen, and choice of the best surgical procedure. We review the previous reports and discuss our own experience to explore the appropriate strategy for patients with resectable stage III/N2 disease, and to identify the factors associated with successful surgical intervention. Among the studies reviewed, the complete resection rate among intention-to-treat cases was correlated well with the 5-year survival rate, whereas the pneumonectomy rate was correlated inversely with the 5-year survival rate. The clinical response rate and downstaging after induction treatment were not associated with survival. Based on these findings, we conclude that complete resection with the avoidance of pneumonectomy is important when selecting candidates for multimodal treatment including radical surgery.
诱导放化疗后的手术干预被设计为可切除 III/N2 期非小细胞肺癌的治愈性治疗。然而,目前没有明确的证据支持这种方法,可能是因为成功的治疗需要某些“技巧”,如适当的患者选择、合适的诱导方案和最佳手术方式的选择。我们回顾了以往的报告,并讨论了我们自己的经验,以探讨可切除 III/N2 期疾病患者的合适策略,并确定与成功手术干预相关的因素。在回顾的研究中,意向治疗病例的完全切除率与 5 年生存率密切相关,而全肺切除术率与 5 年生存率呈反比。诱导治疗后的临床反应率和降期与生存率无关。基于这些发现,我们得出结论,在选择包括根治性手术在内的多模式治疗的候选者时,避免全肺切除术的完全切除是很重要的。